What is B. Riley’s Estimate for ARWR FY2025 Earnings?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at B. Riley lifted their FY2025 earnings estimates for Arrowhead Pharmaceuticals in a research report issued to clients and investors on Thursday, January 2nd. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will earn $1.00 per share for the year, up from their previous forecast of $0.99. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.79) per share.

Several other analysts also recently commented on ARWR. Citigroup reduced their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. Piper Sandler cut their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Friday, December 20th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $43.33.

Arrowhead Pharmaceuticals Stock Up 0.7 %

Shares of Arrowhead Pharmaceuticals stock opened at $19.79 on Monday. The firm has a market cap of $2.46 billion, a price-to-earnings ratio of -3.94 and a beta of 0.97. The stock’s 50-day moving average is $21.05 and its 200 day moving average is $22.64. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. Arrowhead Pharmaceuticals has a one year low of $17.05 and a one year high of $39.83.

Insider Activity at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 26,712 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $21.24, for a total value of $567,362.88. Following the transaction, the chief executive officer now owns 3,688,335 shares in the company, valued at $78,340,235.40. The trade was a 0.72 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William D. Waddill sold 3,748 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $21.90, for a total value of $82,081.20. Following the sale, the director now directly owns 44,125 shares of the company’s stock, valued at $966,337.50. The trade was a 7.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 45,873 shares of company stock valued at $952,553. 4.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC raised its stake in shares of Arrowhead Pharmaceuticals by 3.9% during the 2nd quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock worth $231,022,000 after purchasing an additional 333,333 shares during the period. State Street Corp raised its position in Arrowhead Pharmaceuticals by 8.8% in the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock worth $123,083,000 after acquiring an additional 516,569 shares during the period. Geode Capital Management LLC boosted its stake in Arrowhead Pharmaceuticals by 0.9% in the third quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock valued at $57,426,000 after acquiring an additional 26,171 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Arrowhead Pharmaceuticals by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,006,935 shares of the biotechnology company’s stock valued at $19,504,000 after acquiring an additional 12,574 shares during the period. Finally, Millennium Management LLC grew its position in shares of Arrowhead Pharmaceuticals by 61.9% during the 2nd quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock valued at $13,755,000 after acquiring an additional 202,280 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.